Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Brokerages

Sage Therapeutics, Inc. (NASDAQ:SAGE) has been assigned an average recommendation of “Hold” from the seventeen research firms that are presently covering the stock, Marketbeat reports. Fourteen analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $41.00.

Several brokerages have recently weighed in on SAGE. JPMorgan Chase & Co. raised their price objective on Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, March 26th. Royal Bank of Canada lifted their price target on Sage Therapeutics from $21.00 to $26.00 and gave the stock a “sector perform” rating in a report on Thursday, February 15th. StockNews.com upgraded Sage Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, February 15th. HC Wainwright lifted their price target on Sage Therapeutics from $25.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, February 15th. Finally, Morgan Stanley lifted their price target on Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th.

Institutional Investors Weigh In On Sage Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Advisor Group Holdings Inc. raised its position in Sage Therapeutics by 63.6% during the first quarter. Advisor Group Holdings Inc. now owns 11,406 shares of the biopharmaceutical company’s stock valued at $378,000 after purchasing an additional 4,432 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Sage Therapeutics by 3.0% in the first quarter. Bank of New York Mellon Corp now owns 352,623 shares of the biopharmaceutical company’s stock worth $11,672,000 after purchasing an additional 10,134 shares during the last quarter. MetLife Investment Management LLC bought a new stake in shares of Sage Therapeutics in the first quarter worth $34,000. Vanguard Group Inc. grew its stake in shares of Sage Therapeutics by 1.0% in the first quarter. Vanguard Group Inc. now owns 4,625,003 shares of the biopharmaceutical company’s stock worth $153,088,000 after purchasing an additional 46,762 shares during the last quarter. Finally, First Trust Advisors LP grew its stake in shares of Sage Therapeutics by 4.1% in the first quarter. First Trust Advisors LP now owns 844,652 shares of the biopharmaceutical company’s stock worth $27,958,000 after purchasing an additional 33,218 shares during the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Sage Therapeutics Price Performance

Shares of NASDAQ SAGE opened at $15.63 on Friday. The stock has a market capitalization of $939.52 million, a price-to-earnings ratio of -1.73 and a beta of 0.86. The business has a 50-day moving average of $20.47 and a 200-day moving average of $21.05. Sage Therapeutics has a fifty-two week low of $15.06 and a fifty-two week high of $59.99.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($1.28) by $0.73. The company had revenue of $77.97 million during the quarter, compared to analysts’ expectations of $60.15 million. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. Sage Therapeutics’s revenue for the quarter was up 2621.5% compared to the same quarter last year. During the same quarter last year, the company earned ($2.47) EPS. On average, sell-side analysts expect that Sage Therapeutics will post -6.05 EPS for the current year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.